Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen.

Key facts

Study ID

NCT00428922

Run by

Bhuvaneswari Ramaswamy

People needed

26

Starts

2007-06-14

Expected to finish

2017-02-07

Last updated by the study team

2018-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed breast cancer with evidence of metastatic disease
• HER2 3+ or FISH (fluorescent in situ hybridization)+
• Age ≥ 18 years
• No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.
• No prior chemotherapy in the metastatic setting.

You may not qualify if…

• CNS (central nervous system) metastases
• Prior radiation therapy within the last 4 weeks
• Pregnant (positive pregnancy test) or lactating women
• Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study
• Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.

Where it is running

• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Ohio State University — Columbus, Ohio, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.